Phase 2 Results Of Selinexor In Advanced De-Differentiated (Ddls) Liposarcoma (Seal) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Crossover Study.

JOURNAL OF CLINICAL ONCOLOGY(2018)

引用 19|浏览42
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要